Finnish researchers identify the cause for LGL leukemia

May 16, 2012

Researchers of the University of Helsinki, Helsinki University Central Hospital and Institute for Molecular Medicine Finland, have discovered that a mutation in the STAT3 gene is an underlying cause for LGL leukemia. Since the STAT3 gene is also abnormally expressed in many other cancers and autoimmune diseases, this finding has roused extensive interest. The research will be published in the New England Journal of Medicine on Thursday, May 17, 2012.

LGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease.

One of the key symptoms of LGL disease is a low count of (neutrophils), which may predispose the patients to life-threatening infections.

It was discovered that patients suffering from LGL leukemia have a mutation in the STAT3 gene in a very restricted SH2 area, which has a key effect on the function of the gene. This is not an inherited but a so-called acquired mutation. The cause for the mutation is not known, but probably or some other long-term antigen exposure can be predisposing factors. The STAT3 gene plays a key role in many .

After the finding, the prevalence of the mutation in LGL patients was verified using a larger patient group (77 patients) in cooperation with research groups at the Ohio (Prof. Maciejewski) and Pennsylvania (Prof. Loughran) Universities. It was discovered that 40% of all LGL patients present with the STAT3 mutation.

In the future, this result can be utilized in diagnosing the disease and possibly also in treatment, since the first STAT3 inhibitors are already undergoing early clinical trials. In addition, the research discovered that those LGL patients who had a mutation in the STAT3 gene were also more likely to suffer from rheumatoid arthritis. Hence, the research group intends to clarify next if patients suffering from rheumatoid arthritis can be found with similar gene mutations. If such mutations were to be found this would introduce new opportunities to the pathogenetic mechanisms of rheumatoid arthritis and other autoimmune diseases.

Explore further: Combination drug therapy urged to battle lung cancer

Related Stories

Combination drug therapy urged to battle lung cancer

February 2, 2012
Combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI).

Researchers find important 'target' playing role in tobacco-related lung cancers

February 9, 2012
Researchers at Moffitt Cancer Center in Tampa, Fla., have discovered that the immune response regulator IKBKE (serine/threonine kinase) plays two roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens induce ...

New drug target for kidney disease discovered

April 26, 2011
Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

Recommended for you

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.